David Nelson

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. pmc Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells
    Luyu Yao
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Florida Jacksonville, FL 32206, USA
    Virol J 8:445. 2011
  2. ncbi request reprint Pathogenesis of chronic hepatitis C virus infection
    D R Nelson
    Department of Medicine, University of Florida, Gainesville, USA
    Antivir Ther 3:25-35. 1998
  3. pmc Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3
    David R Nelson
    University of Florida, Gainesville, Florida, USA
    Gastroenterology 139:1267-76. 2010
  4. doi request reprint Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C
    David R Nelson
    University of Florida College of Medicine, Box 100214, Room M 440, Gainesville, Florida 32610 0214, USA
    Clin Gastroenterol Hepatol 7:212-8. 2009
  5. ncbi request reprint Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect
    David R Nelson
    Department of Medicine, University of Florida, 1600 S W Archer Road, PO Box 100214, Gainesville, FL 32610 0214, USA
    Hepatology 38:859-68. 2003
  6. pmc Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    David R Nelson
    Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainsville, USA
    Ann Hepatol 11:15-31. 2012
  7. ncbi request reprint Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation
    D R Nelson
    Center for Liver Transplantation and Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610, USA
    Liver Transpl 7:1064-70. 2001
  8. ncbi request reprint The immunopathogenesis of hepatitis C virus infection
    D R Nelson
    Section of Hepatobiliary Diseases, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, Florida, USA
    Clin Liver Dis 5:931-53. 2001
  9. ncbi request reprint Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders
    D R Nelson
    Section of Hepatobiliary Diseases and Department of Pathology, University of Florida College of Medicine, Gainesville, Florida, USA
    Gastroenterology 118:655-60. 2000
  10. ncbi request reprint Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
    Roberto J Firpi
    Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610, USA
    Liver Transpl 8:1000-6. 2002

Detail Information

Publications83

  1. pmc Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells
    Luyu Yao
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Florida Jacksonville, FL 32206, USA
    Virol J 8:445. 2011
    ..5-IRF3ER cells. The results of this study indicate that IRF-3ER homodimerization is a key step to restore IFN expression in Huh7.5-IRF3ER cells and in achieving its anti-HCV effects...
  2. ncbi request reprint Pathogenesis of chronic hepatitis C virus infection
    D R Nelson
    Department of Medicine, University of Florida, Gainesville, USA
    Antivir Ther 3:25-35. 1998
    ..A better understanding of the host's immune response may provide further insight on the pathogenetic mechanisms involved in development of chronic hepatitis and aid the development of better therapeutic strategies...
  3. pmc Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3
    David R Nelson
    University of Florida, Gainesville, Florida, USA
    Gastroenterology 139:1267-76. 2010
    ....
  4. doi request reprint Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C
    David R Nelson
    University of Florida College of Medicine, Box 100214, Room M 440, Gainesville, Florida 32610 0214, USA
    Clin Gastroenterol Hepatol 7:212-8. 2009
    ..This phase 2 study evaluated the safety/efficacy of albinterferon in CHC patients who had not responded to interferon-based regimens...
  5. ncbi request reprint Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect
    David R Nelson
    Department of Medicine, University of Florida, 1600 S W Archer Road, PO Box 100214, Gainesville, FL 32610 0214, USA
    Hepatology 38:859-68. 2003
    ..In conclusion, long-term rIL-10 therapy appears to decrease disease activity, but also leads to increased HCV viral burden via alterations in immunologic viral surveillance...
  6. pmc Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    David R Nelson
    Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainsville, USA
    Ann Hepatol 11:15-31. 2012
    ..This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin...
  7. ncbi request reprint Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation
    D R Nelson
    Center for Liver Transplantation and Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610, USA
    Liver Transpl 7:1064-70. 2001
    ....
  8. ncbi request reprint The immunopathogenesis of hepatitis C virus infection
    D R Nelson
    Section of Hepatobiliary Diseases, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, Florida, USA
    Clin Liver Dis 5:931-53. 2001
    ..A better understanding of the host's immune response may provide further insight on the pathogenetic mechanisms involved in development of chronic hepatitis and aid the development of better therapeutic strategies...
  9. ncbi request reprint Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders
    D R Nelson
    Section of Hepatobiliary Diseases and Department of Pathology, University of Florida College of Medicine, Gainesville, Florida, USA
    Gastroenterology 118:655-60. 2000
    ..The aim of this study was to determine the effect of IL-10 on hepatic injury in patients with chronic hepatitis C...
  10. ncbi request reprint Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
    Roberto J Firpi
    Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610, USA
    Liver Transpl 8:1000-6. 2002
    ..In summary, combination therapy is a reasonable antiviral option for recurrent HCV infection for established post-LT hepatitis and appears to prevent histological progression of disease if viral eradication is successful...
  11. ncbi request reprint Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line
    Haizhen Zhu
    Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    Hepatology 37:1180-8. 2003
    ..Our results also suggest that IFN-alpha-induced target genes may play an important role in IFN-alpha anti-HCV activity...
  12. pmc Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation
    Roniel Cabrera
    Department of Medicine, Division of Gastroenterology, Hepatology Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, USA
    Am J Clin Oncol 35:345-50. 2012
    ..To evaluate the impact of long-term outcomes of transarterial embolization (TAE) therapy in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) on the waiting list for liver transplantation (LT)...
  13. ncbi request reprint Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation
    Scott J Weston
    Department of Medicine, Oregon Health and Science University, USA
    Hepatology 41:72-81. 2005
    ..Supplementary material for this article can be found on the HEPATOLOGY website (http://interscience. wiley.com/jpages/0270-9139/suppmat/index.html)...
  14. ncbi request reprint Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study
    Robert G Gish
    Department of Medicine, Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, San Francisco, CA, USA
    J Hepatol 47:51-9. 2007
    ..Taribavirin, a ribavirin prodrug, has shown a lower incidence of anemia. We sought to determine the efficacy and safety of taribavirin vs. ribavirin combined with pegylated interferon in patients with chronic hepatitis C (CHC)...
  15. pmc Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro
    Mengde Cao
    Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610 0214, USA
    Int J Radiat Biol 87:71-80. 2011
    ..To determine the radiosensitivity difference of human Cluster of Differentiation (CD)4(+)CD25(+) regulatory T cells (Treg) and effector T cells to low dose gamma ray and elucidate the underlying mechanisms in vitro...
  16. doi request reprint Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients
    Roniel Cabrera
    Hepatobiliary Section, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    Liver Transpl 15:216-22. 2009
    ..In conclusion, these data show the potential utility of the ImmuKnow assay as a means of distinguishing hepatitis C from cellular rejection and its potential usefulness as a marker for outlining the progression of hepatitis C...
  17. ncbi request reprint Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance
    Haizhen Zhu
    Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, 32610, USA
    J Interferon Cytokine Res 25:528-39. 2005
    ..Our study implies that long-term IFN stimulation in vitro selects cells that exhibit alterations in the host Jak-Stat signaling pathway, thereby representing a potential mechanism by which HCV resists IFN therapy...
  18. ncbi request reprint Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system
    Haizhen Zhu
    Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
    Gastroenterology 133:1649-59. 2007
    ..However, the interaction between HCV and hepatocyte innate antiviral defense systems is not understood. The aim of this study was to examine how human hepatocytes respond to HCV infection...
  19. ncbi request reprint Combined hepatic resection and radiofrequency ablation for multiple hepatic adenomas
    Shiro Fujita
    Department of Surgery, College of Medicine, University of Florida, Gainesville, Florida 32610 0286, USA
    J Gastroenterol Hepatol 21:1351-4. 2006
    ..We show three cases without recurrent lesions detected in follow-up examination. Two of the patients have subsequently gone on to carry pregnancies successfully to term...
  20. ncbi request reprint Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis
    Cynthia Levy
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, Florida 32608, USA
    Clin Gastroenterol Hepatol 5:803-8. 2007
    ..We aimed to determine the prevalence of esophageal varices in patients with PBC, to evaluate noninvasive markers of esophageal varices in this population, and to validate the results in an independent set of patients...
  21. doi request reprint Is early recurrence of hepatitis C associated with biliary anastomotic stricture after liver transplantation?
    Shiro Fujita
    Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610 0286, USA
    Transplantation 84:1631-5. 2007
    ..The aim of the current study is to determine if recurrence of hepatitis C affects biliary complications after LT, with special reference to late biliary anastomotic strictures (LBAS)...
  22. ncbi request reprint Novel interferons for treatment of hepatitis C virus
    Virginia Clark
    Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    Clin Liver Dis 13:351-63. 2009
    ..This review highlights novel interferons under development that may offer therapeutic advantages over the formulations currently available...
  23. ncbi request reprint Short recovery time after percutaneous liver biopsy: should we change our current practices?
    Roberto J Firpi
    Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases, University of Florida, 1600 SW Archer Road, PO Box 100214, Gainesville, FL 32610 0214, USA
    Clin Gastroenterol Hepatol 3:926-9. 2005
    ..The aim of this study was to determine whether ambulatory patients requiring percutaneous liver biopsy can be safely discharged after a short recovery time period...
  24. ncbi request reprint Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
    Roberto J Firpi
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610 0214, USA
    Liver Transpl 12:51-7. 2006
    ..In conclusion, Cyclosporine may offer an advantage to Tacrolimus in those patients undergoing interferon-based therapy and should be studied in a prospective randomized trial...
  25. ncbi request reprint Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis
    Giuseppe Morelli
    Division of Gastroenterology and Hepatology and Nutrition Section of Biliary Diseases and Liver Transplantation, University of Florida, Gainesville, FL 32610 0214, USA
    Liver Transpl 12:306-9. 2006
  26. doi request reprint The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients
    David R Nelson
    Clinical and Translational Science Institute, University of Florida, FL 32610, USA
    Liver Int 31:53-7. 2011
    ..However, these dramatic gains will be partially offset by new challenges in viral resistance and increased adverse events...
  27. doi request reprint The natural history of hepatitis C cirrhosis after liver transplantation
    Roberto J Firpi
    Section of Hepatobiliary Diseases, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, FL 32610 0214, USA
    Liver Transpl 15:1063-71. 2009
    ..The Model for End-Stage Liver Disease can stratify risk for decompensation and survival, whereas successful antiviral therapy may be protective...
  28. ncbi request reprint Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation
    Victor I Machicao
    Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, FL 32610 0214, USA
    Liver Transpl 12:754-61. 2006
    ..In conclusion, the implementation of the MELD allocation system is not associated with increased mortality or occurrence of CRD-3 or CRD-4 in the first 2 years after LT...
  29. doi request reprint The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study
    Roberto J Firpi
    Division of Gastroenterology, Hepatology and Nutrition, Section of Hepatobiliary Diseases and Liver Transplantation, Department of Medicine, University of Florida, Gainesville, FL 32610 0214, USA
    Dig Dis Sci 55:196-203. 2010
    ..We performed a pilot study to prospectively determine the antiviral effect of cyclosporine during therapy with PEGalfa-2a and ribavirin in liver transplant recipients with recurrent HCV infection...
  30. doi request reprint Management of viral hepatitis in hematologic malignancies
    Roberto J Firpi
    Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida Gainesville, FL 32610 0214, USA
    Blood Rev 22:117-26. 2008
    ..In this review we will highlight the mechanisms of virus reactivation, clinical manifestations, and management strategies to minimize acute and chronic morbidity in this population...
  31. ncbi request reprint Current and future hepatitis C therapies
    Roberto J Firpi
    Section of Hepatobiliary Diseases and Liver Transplantation, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, Florida 32610 0214, USA
    Arch Med Res 38:678-90. 2007
    ..This review will focus on current therapies for hepatitis C and the most recent advances in the search for new therapies...
  32. pmc Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25)
    Roniel Cabrera
    Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, 1600 SW Archer Rd, PO Box 100214, Gainesville, FL 32610 0214, USA
    Dig Dis Sci 55:484-95. 2010
    ..The mechanisms involved in hepatocellular carcinoma (HCC) establishing an immunologically tolerogenic tumor environment remain poorly characterized...
  33. pmc Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication
    Haizhen Zhu
    Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida 32610, USA
    Virol J 2:80. 2005
    ..The effectiveness of IL-28A antiviral activity and its synergistic effect on IFN-alpha indicate that IL-28A may be potentially used to treat HCV chronic infection...
  34. ncbi request reprint Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection
    Roberto J Firpi
    Section of Hepatobiliary Diseases, Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, PO Box 100214, JHMHC, Gainesville, FL 32610 0214, USA
    Liver Transpl 9:57-61. 2003
    ..The most common side effects were headache, nausea, and diarrhea. Mycophenolate alone does not appear to have a significant antiviral or biochemical effect in patients with chronic hepatitis C...
  35. ncbi request reprint Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research
    Shawna L Ehlers
    Department of Clinical and Health Psychology, University of Florida Health Science Center, Gainesville FL 32610 0165, USA
    Liver Transpl 10:412-7. 2004
    ....
  36. ncbi request reprint One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
    Roberto J Firpi
    Division of Gastroenterology, Hepatology, and Nutrition Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610 0214, USA
    Liver Transpl 10:1240-7. 2004
    ..A liver biopsy performed at 1 year posttransplant can help identify those patients more likely to develop progressive disease and may allow better targeting of antiviral therapy...
  37. ncbi request reprint Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
    Manal F Abdelmalek
    Department of Medicine, Section of Hepatobiliary Diseases University of Florida, Gainesville, FL 32610 0214, USA
    Liver Transpl 10:199-207. 2004
    ..05). In conclusion, loss of HCV after treatment of recurrent chronic hepatitis C with interferon and ribavirin is durable, and the durability of the SVR is associated with improvement in hepatic inflammation and regression of fibrosis...
  38. pmc Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus
    Hongyan Liu
    Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, United States of America
    PLoS ONE 7:e46631. 2012
    ..In conclusion, hepcidin can induce intracellular antiviral state while HCV has a strategy to suppress hepcidin expression. This may be a novel mechanism by which HCV circumvents hepatic innate antiviral defense...
  39. pmc Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells
    Mengde Cao
    Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610 0214, USA
    Cell Biol Int 33:565-71. 2009
    ..Our findings suggest that radiotherapy may be an important strategy to alter the immunologic balance of Tregs and effector cells in cancer therapy...
  40. ncbi request reprint Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease
    Diana M Toivola
    Department of Medicine, Palo Alto VA Medical Center, Stanford University School of Medicine Digestive Disease Center, Palo Alto, CA 94304, USA
    Hepatology 40:459-66. 2004
    ..In conclusion, site-specific keratin phosphorylation in liver disease is a progression marker when increased and a likely regression marker when decreased...
  41. ncbi request reprint Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells
    Mengde Cao
    Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610 0214, USA
    Lab Invest 87:582-90. 2007
    ..In conclusion, these results strongly suggest that tumor-related factors not only induce and expand CD4(+)CD25(+) cells, but also enhance their suppressor ability...
  42. ncbi request reprint CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity
    Chen Liu
    Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, USA
    Hepatology 37:1335-42. 2003
    ..This T-cell/HCV subgenomic replicon system represents a model for the investigation of CD8 cell interaction with HCV-infected hepatocytes...
  43. doi request reprint Factors predicting survival after transjugular intrahepatic portosystemic shunt creation: 15 years' experience from a single tertiary medical center
    Jen Jung Pan
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, 1600 Southwest Archer Road, Room M 440, Gainesville, FL 32610, USA
    J Vasc Interv Radiol 19:1576-81. 2008
    ..This retrospective analysis was conducted to identify factors predictive of survival after transjugular intrahepatic portosystemic shunt (TIPS) creation...
  44. doi request reprint Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Gastroenterol Hepatol 6:242-7. 2008
    ..We hypothesized that a noninvasive test of liver fibrosis can accurately stage liver fibrosis. We prospectively evaluated the FIBROSpect II (FSII) biomarker panel versus pathology assessment and a quantitative measure of fibrosis...
  45. pmc Mortality following operations for lower extremity peripheral arterial disease
    Tracie C Collins
    Department of Medicine, Division of General Internal Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Vasc Health Risk Manag 6:287-96. 2010
    ..We sought to identify risk factors associated with mortality following surgery for peripheral arterial disease (PAD)...
  46. ncbi request reprint An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection
    Roniel Cabrera
    Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610 0214, USA
    Hepatology 40:1062-71. 2004
    ..In conclusion, CD4(+)CD25(+) T lymphocytes constitute a highly differentiated population and appear to play a role in viral persistence by suppressing HCV-specific T cell responses in a cell-cell contact manner...
  47. ncbi request reprint Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis
    Xian Zhang Shang
    Department of Pathology, Immunology and Laboratory Medicine, University of Florida, P O Box 100275, Gainesville, FL 32610, USA
    Lab Invest 84:332-41. 2004
    ..Our study suggests that mutant beta-catenin can promote cell proliferation and cell survival ability, but the stabilized beta-catenin alone is insufficient for completely oncogenic transformation...
  48. doi request reprint New therapies in the management of hepatitis C virus
    Anthony J Michaels
    Division of Hepatology and Liver Transplantation, Shands Hospital, University of Florida, Gainesville, Florida, USA
    Curr Opin Gastroenterol 26:196-201. 2010
    ..This article will discuss the most promising up-to-date hepatitis C virus antiviral therapies in clinical investigation as well as the associated clinical trial results...
  49. pmc Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome
    Andrew F Shorr
    Department of Medicine, Section of Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA
    Crit Care 10:R92. 2006
    ..The objective of this study was to determine whether early directional changes in protein C levels correlate with outcome...
  50. ncbi request reprint A brief psychological intervention to improve adherence following transplantation
    Gail L Lisson
    Department of Clinical and Health Psychology, University of Florida, Gainesville, FL 32610 0165, USA
    Ann Transplant 10:52-7. 2005
    ..This intervention has been very favorably received by patients, caregivers, transplant physicians, and nurse coordinators...
  51. ncbi request reprint Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease
    Manal F Abdelmalek
    Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, Florida, USA
    Clin Gastroenterol Hepatol 4:1162-9. 2006
    ..An association between nonalcoholic fatty liver disease (NAFLD) and the insulin resistance (IR) syndrome exists. Familial clustering of IR may support a genetic predisposition to NAFLD or cryptogenic cirrhosis (CC)...
  52. pmc Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
    Andrew F Shorr
    Department of Medicine, Section of Pulmonary and Critical Care Medicine, Washington Hospital Center, Irving Street, Washington, District of Columbia 20010, USA
    Crit Care 12:R45. 2008
    ..The goal of this study was to identify a dependable, sensitive measure with which to monitor disease progression and response in patients during DrotAA treatment...
  53. ncbi request reprint Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation
    Karim Samara
    Department of Internal Medicine, University of Florida, Gainesville, Florida 32608 0214, USA
    Dig Dis Sci 51:1226-9. 2006
  54. ncbi request reprint A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 11:941-9. 2005
    ..Further studies are required to determine whether the drug has beneficial effects in this group of patients...
  55. ncbi request reprint Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 13:747-60. 2008
    ..The treatment paradigm for chronic hepatitis C continues to evolve and will eventually incorporate new drugs as they are approved...
  56. doi request reprint Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27514, USA
    Hepatology 48:1033-43. 2008
    ..The arm with the higher doses of both drugs was less well-tolerated than the other regimens...
  57. ncbi request reprint The financial burden of transplantation: a single-center survey of liver and kidney transplant recipients
    James R Rodrigue
    The Transplant Center and the Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Transplantation 84:295-300. 2007
    ..These findings highlight the potential financial impact of transplantation on patients and families, and they have implications for assisting patients in managing out-of-pocket expenses after transplantation...
  58. ncbi request reprint Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis
    William L Macias
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Crit Care Med 32:2385-91. 2004
    ..To elucidate sources of variability in the estimate of treatment effects in a successful phase 3 trial in severe sepsis and to assess their implications on the design of future clinical trials...
  59. ncbi request reprint Predictors of long-term mortality in patients with cirrhosis of the liver admitted to a medical ICU
    Thomas R Gildea
    Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, 9500 Euclid Ave, G62, Cleveland, OH 44195, USA
    Chest 126:1598-603. 2004
    ..The long-term survival of patients with cirrhosis of the liver admitted to the ICU has not been described...
  60. ncbi request reprint International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH
    Andreas Sashegyi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 22:1001-12. 2006
    ....
  61. ncbi request reprint Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial
    Pierre Francois Laterre
    Department of Critical Care, St Luc University Hospital, UCL, Brussels, Belgium
    Crit Care Med 32:2207-18. 2004
    ..To compare differences in hospital mortality and resource use in adult severe sepsis subjects randomized to receive drotrecogin alfa (activated) (DrotAA) or placebo in the PROWESS trial...
  62. ncbi request reprint Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:901-8. 2006
    ..05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-alpha...
  63. ncbi request reprint Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C
    Mark W Russo
    Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology and Disease and University of North Carolina at Chapel Hill, NC 27599 7080, USA
    Liver Transpl 11:1235-41. 2005
    ..004). In conclusion, hepatic stellate cell activation early after liver transplantation complements traditional testing for identifying liver transplant recipients with hepatitis C at greatest risk for developing advanced fibrosis...
  64. ncbi request reprint Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis
    Lakhmir S Chawla
    Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC 20037, USA
    Clin J Am Soc Nephrol 2:22-30. 2007
    ..IL-6 data and the absence of correlation with measures of hypotension (e.g., mean arterial pressure, dosage of vasopressors) support the notion that inflammation is a significant component of AKI in SS...
  65. ncbi request reprint C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study
    Carlos A Labarrere
    Methodist Research Institute, Clarian Health Partners, Methodist, Indiana University, Riley Hospitals, Indianapolis, IN 46202, USA
    Lancet 360:1462-7. 2002
    ..We investigated whether C-reactive protein, known to stimulate ICAM-1, was associated with increased ICAM-1 concentration and subsequent development of coronary artery disease...
  66. ncbi request reprint Effect of cigarette smoking on levels of seminal oxidative stress in infertile men: a prospective study
    Ramadan A Saleh
    Center for Advanced Research in Human Reproduction, Infertility, and Sexual Function, Urological Institute, The Cleveland Clinic Foundation, Ohio 44195, USA
    Fertil Steril 78:491-9. 2002
    ..To investigate levels of seminal oxidative stress (OS) and sperm quality in a group of infertile men with a history of cigarette smoking...
  67. ncbi request reprint Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure
    Jean Francois Dhainaut
    Department of Intensive Care, Cochin Hospital, AP HP, Cochin Institute, Cochin Port Royal Medical School, Paris V University, Paris, France
    Crit Care Med 33:341-8. 2005
    ..To determine whether changes in coagulation biomarkers during the first day of severe sepsis correlate with progression from single to multiple organ failure and subsequent death...
  68. ncbi request reprint Underlying disorders and their impact on the host response to infection
    Jean Francois Dhainaut
    Intensive Care and Emergency Department, Cochin University Hospital, Rene Descartes University, Paris, France
    Clin Infect Dis 41:S481-9. 2005
    ..Although innate immunity seems not to be actually blunted in patients with underlying disorders, the underlying disorder itself contributes to the severity of the physiological response to sepsis, thereby resulting in a worse outcome...
  69. ncbi request reprint Peritoneal fluid leptin is associated with chronic pelvic pain but not infertility in endometriosis patients
    Mohamed A Bedaiwy
    Center for Advanced Research in Human Reproduction, Infertility, and Sexual Function, Department of Obstetrics Gynecology, Urological Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Reprod 21:788-91. 2006
    ..The objective of this study was to evaluate the peritoneal fluid levels of leptin in patients with endometriosis and idiopathic infertility and compare them with a control group of tubal ligation/reanastomosis patients...
  70. ncbi request reprint Interleukin-10 inhibition of nitric oxide biosynthesis involves suppression of CAT-2 transcription
    Chun Jen Huang
    Department of Anesthesiology, Mackay Memorial Hospital
    Nitric Oxide 6:79-84. 2002
    ..Moreover, our data suggests that transcriptional control of CAT-2 plays a role in IL-10 mediated influences upon nitric oxide biosynthesis...
  71. pmc Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis
    William L Macias
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Crit Care 9:R607-22. 2005
    ..Such an interaction might warrant a change in the assumptions that underlie current trial designs...
  72. ncbi request reprint Non-immunologic vascular failure of the transplanted heart
    Carlos A Labarrere
    Methodist Research Institute, Clarian Health Partners Methodist, Indiana University and Riley Hospitals, Indianapolis, Indiana 46202, USA
    J Heart Lung Transplant 22:236-40. 2003
  73. ncbi request reprint Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)
    Steven M Opal
    Brown University School of Medicine, Providence, RI, USA
    Clin Infect Dis 37:50-8. 2003
    ..Results demonstrate that DrotAA, administered as an adjunct to standard anti-infective therapy, can improve the rate of survival for patients who develop severe sepsis regardless of causative microorganism...
  74. ncbi request reprint Severe protein C deficiency predicts early death in severe sepsis
    William L Macias
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Crit Care Med 32:S223-8. 2004
    ..To explore the relationship between measures of baseline disease severity and survival time in patients with severe sepsis...
  75. ncbi request reprint International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety
    Pierre Francois Laterre
    Department of Critical Care Medicine, Hôpital St Luc, Universite Catholique de Louvain, B 1200 Brussels, Belgium
    J Crit Care 22:142-52. 2007
    ..Initial analyses evaluated the 28-day survival in the placebo group and further assessed the treatment effect of drotrecogin alfa (activated) (DrotAA)...
  76. pmc The protein C pathway: implications for the design of the RESPOND study
    Burkhard Vangerow
    Eli Lilly Critical Care Europe, Air Center, 1214 Vernier Geneva, Switzerland
    Crit Care 11:S4. 2007
    ....
  77. ncbi request reprint A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:35-45. 2006
    ..These results support further clinical studies of albumin-IFN-alpha for the treatment of patients with chronic hepatitis C...
  78. ncbi request reprint Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C
    S Betty Yan
    Lilly Research Laboratories, Indianapolis, IN, USA
    Crit Care Med 32:S239-46. 2004
    ....
  79. pmc Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
    Mark D Williams
    Crit Care 10:424. 2006
  80. ncbi request reprint Hepatic mucormycosis in a renal transplant recipient
    Kristin L Mekeel
    Transplantation 79:1636. 2005
  81. ncbi request reprint Effects of drotrecogin alfa (activated) in human endotoxemia
    Andre C Kalil
    UMDNJ Robert Wood Johnson Medical School, Department of Surgery, New Brunswick, New Jersey 08903, USA
    Shock 21:222-9. 2004
    ..These results suggest a novel role for drotrecogin alfa (activated) in the human endotoxin model...
  82. ncbi request reprint Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database
    Didier Payen
    Surgery 142:426-7. 2007
  83. ncbi request reprint Sexual dysfunction in men undergoing infertility evaluation: a cohort observational study
    Ramadan A Saleh
    Center for Advanced Research in Human Reproduction, Infertility, and Sexual Function, Urological Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Fertil Steril 79:909-12. 2003
    ..To study psychosexual problems in men undergoing infertility evaluation...

Research Grants8

  1. CELLULAR IMMUNE RESPONSE IN CHRONIC HEPATITIS C
    David Nelson; Fiscal Year: 2003
    ..These studies will provide insight into basic immunologic principles associated with the host's immune response to this viral infection, as well as provide the basis for new interventional strategies. ..
  2. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2005
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  3. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2006
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  4. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2007
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  5. Basic & Clinical Research Training in Gastroenterology and Hepatology
    David Nelson; Fiscal Year: 2007
    ..Since 2002 the Gl Division has trained 21 Gl fellows, with 12 still in training. Of these 21 individuals, 2 are African American (10%), 2 are Hispanic (10%), and 7 are women (33%). ..
  6. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2009
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..